A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
Sara Carrillo De AlbornozKhai Li ChaiAlisa M HigginsDennis PetrieErica M WoodZoe K McQuiltenPublished in: International journal of technology assessment in health care (2024)
Our review highlighted key gaps in the literature: the cost-effectiveness of Ig in patients with hematological malignancies is very uncertain. Despite increasing Ig use worldwide, there are limited data regarding the total direct and indirect costs of treatment, and the optimal use of Ig and downstream implications for healthcare resource use and costs remain unclear. Given the paucity of evidence on the costs and cost-effectiveness of Ig treatment in this population, further health economic research is warranted.